Serina Therapeutics Inc's Business Segments

The company is a clinical-stage biotechnology firm developing drug candidates using its proprietary POZ drug delivery technology to treat neurological diseases and other conditions. The POZ technology employs a synthetic, water-soluble polymer called poly(2-oxazoline) to enhance drug efficacy and safety by enabling precise drug loading and controlled release through long-acting subcutaneous injections. This technology aims to address limitations of existing polymers such as polyethylene glycol (PEG) by offering easier synthesis, greater stability, reduced immunogenicity, higher drug loading capacity, no tissue accumulation, and the capacity to attach targeting molecules. The lead product candidate, SER 252 (POZ-apomorphine), is in clinical development for advanced Parkinson’s disease, designed to provide continuous dopaminergic stimulation via weekly injections. Another candidate, SER 214 (a POZ conjugate of rotigotine), completed a Phase Ia study but is not being advanced internally. The company is also investigating applications of POZ technology in antibody drug conjugates and lipid nanoparticle RNA vaccines, with plans to develop some candidates internally and others through partnerships or out-licensing. The FDA cleared the IND for SER 252 in January 2026, and a Phase 1b trial commenced in February 2026. The company’s strategy includes advancing its pipeline, expanding collaborations, and applying POZ technology across multiple therapeutic areas.

Serina Therapeutics Inc. is a biopharmaceutical company focused on the development of innovative drug delivery systems and therapeutic solutions primarily utilizing its proprietary platform technologies. The company aims to enhance therapeutic efficacy while minimizing side effects through its advanced formulation and delivery methods.

Segments

1. Drug Delivery Innovations
- Serina Therapeutics specializes in the development of advanced drug delivery technologies that support the administration of a wide range of therapeutic agents. This segment focuses on optimizing the bioavailability and pharmacokinetics of drugs through novel formulations.

2. Therapeutic Development
- The company is also engaged in the research and development of therapeutic products that target specific diseases or medical conditions. This includes both small molecules and biologics, aiming to create treatments that are more effective and have improved safety profiles.

3. Collaborative Partnerships
- Serina Therapeutics often collaborates with academic institutions, research organizations, and other industry players to leverage synergies in drug formulation and delivery technology. These partnerships enhance the company’s pipeline and facilitate the advancement of new therapies.

Products and Services

1. SUSTAIN™ Technology
- One of the flagship innovations of Serina is the SUSTAIN™ technology platform, which is designed to provide sustained release of therapeutic agents. This technology allows for extended dosing intervals, thereby improving patient adherence and overall treatment outcomes.

2. Polymer-Based Delivery Systems
- Serina Therapeutics utilizes a range of biocompatible polymers that can encapsulate drugs and facilitate their controlled release. These systems are particularly useful for therapeutics that require localized delivery or sustained exposure to achieve maximum therapeutic effects.

3. Formulation Development Services
- The company offers formulation development services to other pharmaceutical companies looking to improve their drug products. By using Serina’s expertise in drug delivery mechanisms, clients can enhance the performance of their compounds and expedite their time to market.

4. Clinical Development Support
- Serina provides guidance and support for clinical development phases, helping partners navigate regulatory requirements, optimize study designs, and execute clinical trials that evaluate the efficacy and safety of their drug formulations.

5. Intellectual Property Portfolio
- Serina Therapeutics has built a robust intellectual property portfolio around its research and technologies. This includes patents for proprietary formulations and delivery methods, providing a competitive advantage in the marketplace.

6. Custom Development Projects
- The company is open to engaging in custom development projects, where it collaborates with pharmaceutical companies and biotech firms to create tailored solutions for specific therapeutic needs or challenges in drug delivery.

Therapeutic Areas of Focus

1. Pain Management
- Serina Therapeutics explores options for pain management therapies, aiming to develop formulations that provide effective pain relief while minimizing side effects commonly associated with traditional analgesics.

2. Oncology
- With a significant need for novel delivery mechanisms in cancer treatments, Serina is involved in developing therapeutics that can effectively target tumor sites, enhancing drug concentration in the affected areas while reducing systemic toxicity.

3. Neurological Disorders
- The company is researching formulations intended for treating neurological conditions, where targeted delivery can be crucial due to the complex nature of the blood-brain barrier and the need for precise therapeutic effects.

4. Chronic Diseases
- Serina also focuses on chronic diseases that require long-term management, developing drug delivery systems that can provide consistent therapeutic levels over extended periods.

Conclusion

Serina Therapeutics Inc. has positioned itself in the biopharmaceutical landscape through its commitment to improving drug delivery systems and developing effective therapeutic solutions. With a focus on innovative technologies and strategic collaborations, the company aims to meet the evolving needs of the healthcare sector while addressing significant unmet medical needs.